JP2024525837A - アンチセンスオリゴヌクレオチド（ａｓｏ）遺伝子阻害及び処置 - Google Patents

アンチセンスオリゴヌクレオチド（ａｓｏ）遺伝子阻害及び処置 Download PDF

Info

Publication number
JP2024525837A
JP2024525837A JP2024502210A JP2024502210A JP2024525837A JP 2024525837 A JP2024525837 A JP 2024525837A JP 2024502210 A JP2024502210 A JP 2024502210A JP 2024502210 A JP2024502210 A JP 2024502210A JP 2024525837 A JP2024525837 A JP 2024525837A
Authority
JP
Japan
Prior art keywords
aso
seq
jak2
ighmbp2
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525837A5 (https=
Inventor
プルズィホドゼン、バルトロミエイ
スミースゼク、サンドラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of JP2024525837A publication Critical patent/JP2024525837A/ja
Publication of JP2024525837A5 publication Critical patent/JP2024525837A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024502210A 2021-07-15 2022-07-13 アンチセンスオリゴヌクレオチド（ａｓｏ）遺伝子阻害及び処置 Pending JP2024525837A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163222336P 2021-07-15 2021-07-15
US63/222,336 2021-07-15
US202163224362P 2021-07-21 2021-07-21
US63/224,362 2021-07-21
PCT/US2022/073668 WO2023288240A1 (en) 2021-07-15 2022-07-13 Antisense oligonucleotide (aso) gene inhibition and treatment

Publications (2)

Publication Number Publication Date
JP2024525837A true JP2024525837A (ja) 2024-07-12
JP2024525837A5 JP2024525837A5 (https=) 2025-06-23

Family

ID=82850241

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502210A Pending JP2024525837A (ja) 2021-07-15 2022-07-13 アンチセンスオリゴヌクレオチド（ａｓｏ）遺伝子阻害及び処置

Country Status (8)

Country Link
EP (1) EP4370133A1 (https=)
JP (1) JP2024525837A (https=)
KR (1) KR20240037996A (https=)
AU (1) AU2022312494A1 (https=)
CA (1) CA3224471A1 (https=)
IL (1) IL309813A (https=)
MX (1) MX2024000636A (https=)
WO (1) WO2023288240A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121039279A (zh) * 2023-05-05 2025-11-28 万达制药公司 反义寡核苷酸(aso)基因抑制和治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014161046A1 (en) * 2013-04-04 2014-10-09 The Walter And Eliza Hall Institute Of Medical Research Methods of treating diseases characterized by excessive wnt signalling
WO2017214463A1 (en) * 2016-06-09 2017-12-14 The Regents Of The University Of California Compositions and methods for treating cancer and biomarkers to detect cancer stem cell reprogramming and progression

Also Published As

Publication number Publication date
AU2022312494A9 (en) 2024-01-25
MX2024000636A (es) 2024-02-06
WO2023288240A8 (en) 2023-12-14
AU2022312494A1 (en) 2024-01-18
EP4370133A1 (en) 2024-05-22
KR20240037996A (ko) 2024-03-22
CA3224471A1 (en) 2023-01-19
WO2023288240A1 (en) 2023-01-19
IL309813A (en) 2024-02-01
WO2023288240A9 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
JP6855480B2 (ja) 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法
EP2841067A2 (en) A drug screening platform for rett syndrome
CA3162618A1 (en) Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
EP4005570A1 (en) Use of pridopidine for treating rett syndrome
EP3883597A2 (en) Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
AU2014346840B2 (en) Methods and materials for treating hematological malignancies
JP2024525837A (ja) アンチセンスオリゴヌクレオチド（ａｓｏ）遺伝子阻害及び処置
CN111356452A (zh) 用于治疗神经病况的方法和组合物
US20240376478A1 (en) Antisense Oligonucleotide (ASO) Gene Inhibition and Treatment
CN117897161A (zh) 反义寡核苷酸(aso)基因抑制和治疗
Koller et al. Antagonizing Il10 and Il4 signaling via intracerebral decoy receptor expression attenuates Aβ accumulation
CN117043339A (zh) 用于治疗认知障碍的微小rna 195组合物和方法
JP2024529930A (ja) 低減されたオフターゲット効果を有する修飾低分子干渉ｒｎａ分子
CN121039279A (zh) 反义寡核苷酸(aso)基因抑制和治疗
JP7812535B2 (ja) 新型コロナウイルス感染症後遺症治療薬のスクリーニング方法及び新型コロナウイルス感染症後遺症モデル動物の製造方法
He et al. Targeting Fgr-STAT3 Mediated Autophagy Inhibition in the Spinal Cord Alleviates Neuropathic Pain in Rats: L. He et al.
RU2839162C2 (ru) Молекула олигомерной нуклеиновой кислоты и ее применение
KR102315736B1 (ko) Apoe4 rna 특이적 트랜스-스플라이싱 리보자임 및 이의 용도
US20220184029A1 (en) Compositions and methods for treating neuroblastoma
US20220002726A1 (en) Methods of safe administration of an irf5 antisense oligonucleotide
KR101693186B1 (ko) ＰＡＮ-ＥｒｂＢ 억제제의 암 치료 효과 예측에 관한 정보 제공 방법
AU2024352343A1 (en) Antisense oligonucleotides for the treatment of canavan disease
WO2025052391A1 (en) Antisense oligonucleotides targeting the cftr 3849+10 kilobase (kb) c->t splicing mutation
WO2023250249A1 (en) Hmgb1 inhibitors for treatment of apoe4-related tauopathies including alzheimer's disease
Zagozewski et al. PDTM-28. AN OTX2-PAX3 SIGNALLING AXIS REGULATES GROUP 3 MEDULLOBLASTOMA CELL FATE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250613